Articles tagged "Induction therapy"

2022 American Transplant Congress
A Single Center Experience of Simultaneous Heart-Kidney Transplantation
A. Samra¹, A. Mattoo²
¹Nephrology, New York University Langone Transplant Institute, New York, NY, ²New York University Langone Transplant Institute, New York, NY
*Purpose: Currently there are no UNOS guidelines regarding the selection criteria required for simultaneous heart-kidney transplant recipients (SHKT). As of 2018 our center has begun…
2022 American Transplant Congress
Costs Associated with Induction Therapy for Pediatric Kidney Transplantation
N. M. Rodig¹, H. Pizzo², D. Levy Erez³, T. Richardson⁴, M. Somers¹
¹Boston Children's Hospital, Boston, MA, ²Cedars-Sinai Medical Center, Los Angeles, CA, ³Children’s Hospital of Philadelphia, Philadelphia, PA, ⁴Children's Hospital Association, Lenexa, KS
*Purpose: Choice of induction agent for pediatric kidney transplantation (KTx) is often based upon patient characteristics and center practice; costs associated with this choice have…
2022 American Transplant Congress
Fixed-Dose Rituximab for Pre-Transplant DSA in Kidney Transplant Recipients
K. Progar¹, K. Kurwicki², N. Nesselhauf³, J. Hagopian⁴, S. January⁵, H. Wijeweera⁶, M. McCloskey⁷, M. Merzkani⁸, R. Delos Santos⁹
¹Transplant, Barnes-Jewish Hospital, St. Louis, MO, ²SSM Health Saint Louis University Hospital, Saint Louis, MO, ³Barnes-Jewish Hospital, Edwardsville, IL, ⁴Pharmacy, University of Michigan, Ann Arbor, MI, ⁵Pharmacy, Barnes-Jewish Hospital, Saint Louis, MO, ⁶Washington University, Saint Louis, MO, ⁷Barnes-Jewish Hospital, St. Louis, MO, ⁸Washington University, St Louis, MO, ⁹Transplant, Washington University, St. Louis, MO
*Purpose: Donor specific antibodies (DSAs) occur in 15-30% of kidney transplant recipients (KTRs) and are associated with rejection and graft loss. Rituximab (RTX), an antiCD20…
2022 American Transplant Congress
Thymoglobulin Induction Protocol: Quality Improvement Project via Clinical Audit
S. Mouawad¹, J. Dann¹, A. Kumar², S. Rao³
¹University of Virginia Health System, Charlottesville, VA, ²Nephrology, University of Virginia, Charlottesville, VA, ³University of Virginia, Charlottesville, VA
*Purpose: The aim of our study was to analyze the adequacy of the thymoglobulin (rATG) induction protocol for the expanding and higher complexity kidney transplant…
2022 American Transplant Congress
Benefits and Risks of Induction Immunosuppression Therapy in Pediatric Liver Transplantation
T. Bittermann, P. Abt
University of Pennsylvania, Philadelphia, PA
*Purpose: To investigate trends in induction therapy use in pediatric liver transplantation (LT) in the U.S. and evaluate the potential benefits and risks of induction…
2022 American Transplant Congress
A Single-Center’s Outcomes of Combined Heart-Liver Transplantation
R. W. Lincoln¹, K. Kalvakuri², A. Guha², A. Bhimaraj², E. E. Suarez², A. Saharia³, C. M. Mobley³, F. Amirkhosravi³, J. Krisl¹
¹Pharmacy, Houston Methodist Hospital, Houston, TX, ²DeBakey Heart and Vascular Associates, Houston Methodist Hospital, Houston, TX, ³Surgery, Houston Methodist Hospital, Houston, TX
*Purpose: The purpose of this study was to evaluate rejection outcomes in our combined heart-liver transplant (CHLT) recipients at 6 months.*Methods: This is a retrospective,…
2022 American Transplant Congress
Intraoperative Kinetics of Pro-Inflammatory Markers and Delayed-Graft Function During Kidney Transplantation
P. A. Wadsworth, H. L. Stevenson, M. L. Kueht
University of Texas Medical Branch, Galveston, TX
*Purpose: Detailed molecular changes associated with allograft reperfusion have been poorly defined and current methods of predicting delayed graft function (DGF) after kidney transplantation are…
2022 American Transplant Congress
Selective CD28 Blockade Impacts T Cell Differentiation During Hematopoietic Reconstitution Following Lymphodepletion
J. Habib, D. Liu, R. L. Crepeau, M. E. Wagener, M. L. Ford
Emory University, Atlanta, GA
*Purpose: Costimulation blockade targeting the CD28 pathway provides improved long-term transplant survival without the nephrotoxicity of calcineurin inhibitors. However, treatment with the CTLA-4Ig fusion protein…
2022 American Transplant Congress
Outcomes of Primary Simultaneous Pancreas-Kidney Transplants by Induction Agent in the United States
A. Cerise¹, T. Shaker¹, K. Ramanathan¹, S. Jackson², R. Kandaswamy¹, S. Riad³
¹Surgery, University of Minnesota, Minneapolis, MN, ²Analytics, MHealth-Fairview, Minneapolis, MN, ³Medicine, University of Minnesota, Minneapolis, MN
*Purpose: Induction immunosuppression choice for simultaneous pancreas-kidney (SPK) transplants varies widely in the United States. We examined the association between induction agents and outcomes of…
2022 American Transplant Congress
Impact of Induction Immunosuppression on Renal Recovery in Adult Liver Transplant Recipients – A Single Center Experience
T. Zurick¹, D. Bruno², D. Kumar³, R. Winstead¹, C. Song¹, A. Brown¹, S. Sterling¹, I. Yakubu¹
¹Pharmacy, VCU Health System, Richmond, VA, ²Transplant Surgery, VCU Health System, Richmond, VA, ³Transplant Nephrology, VCU Health System, Richmond, VA
*Purpose: Renal dysfunction after liver transplantation (LT) is associated with increased morbidity and mortality. Early exposure to calcineurin inhibitors (CNI) is a risk factor for…